Protocols

Takeda inks discovery pact with Stanford; Jounce taps Ariad vet Cole as new CBO

Takeda’s research group in Cambridge, MA has struck a deal to work more closely with researchers at Stanford with an eye to moving more drugs through R&D. “Takeda’s alliance with Stanford demonstrates our commitment to advancing medicines as quickly and efficiently as possible – from drug discovery to development and ultimately to patients,” said Juan Harrison, vice president, head of strategic academic alliances, Takeda.

⇨ Cambridge, MA-based Jounce Therapeutics $JNCE has picked Ariad vet Hugh Cole as its new chief business officer and head of corporate development. Cole is credited with doing nine deals for Ariad.

⇨ The microcap biotech Tracon Pharmaceuticals touted new Phase I/II data from a small, single-arm study combining TRC105 and Nexavar (sorafenib) in hepatocellular cancer. The dose-ranging study included 26 patients, with an ORR of 25%; 33% if you just look at the two top doses.



The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biomanufacturing